Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BioMarin Pharmaceutical Inc. - Common Stock (NQ: BMRN )

68.81 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Feb 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioMarin Pharmaceutical Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Have Million-Dollar Gene Therapies Finally Reached An Inflection Point?
Gene therapies are clearing the FDA and reaching seriously ill patients. They could cost millions. 
Via Investor's Business Daily
Exposures Product Safety
What 16 Analyst Ratings Have To Say About Biomarin Pharmaceutical
Via Benzinga
4 Preeminent Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
The innovation-fueled Nasdaq Composite remains 13% below its all-time high, which means bargains can still be found. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
4 Unforgettable Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
With the growth-driven Nasdaq Composite still 14% below its record-closing high, deals abound. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Earnings Outlook For Biomarin Pharmaceutical
Via Benzinga
What 9 Analyst Ratings Have To Say About Biomarin Pharmaceutical
Via Benzinga
What 13 Analyst Ratings Have To Say About Biomarin Pharmaceutical
Via Benzinga
Biomarin's Q2 Beat Street View, Raises Voxzogo Annual Guidance Driven By Global Demand
Biomarin Pharmaceutical Inc (NASDAQ: BMRN) reported a Q2 adjusted EPS of $0.54, higher than $0.41 a year ago and beating the  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 27, 2023
Via Benzinga
3 Biotech Stocks to Make Your ‘Get Rich’ Dreams Come True
These high return biotech stocks offer tremendous upside ahead and are likely to soar on the back of several growth drivers 
Via InvestorPlace
What 9 Analyst Ratings Have To Say About Biomarin Pharmaceutical
Via Benzinga
Death Cross Looms Over Biomarin Pharmaceutical Investors
Via Benzinga
What 17 Analyst Ratings Have To Say About Biomarin Pharmaceutical
Via Benzinga
Earnings Scheduled For July 31, 2023
Companies Reporting Before The Bell • Immunogen (NASDAQ:IMGN) is estimated to report quarterly loss at $0.16 per share on revenue of $42.84 million. 
Via Benzinga
A Preview Of Biomarin Pharmaceutical's Earnings
Via Benzinga
Is BioMarin Ready To Rebound After FDA Approval Of Roctavian?
BioMarin gets FDA approval for Roctavian and earned an upgrade because of it; shares may be ready to rebound but there are still hurdles. 
Via MarketBeat
Exposures Product Safety
BioMarin Presents ~20% Upside Amid Voxzogo's Success and Slow Roctavian Uptake, Analyst Says
BMO Capital Markets has upgraded BioMarin Pharmaceutical Inc (NASDAQ: BMRN) to Outperform from Market Perform, and the price target remains at $102,  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 5, 2023
Via Benzinga
BioMarin's Roctavian US Launch: Focus on Commercial Strategy Amid EU Failures, Analyst Points Out
On Thursday, The FDA approved BioMarin Pharmaceutical Inc's (NASDAQ: BMRN) Roctavian (valoctocogene roxaparvovec-rvox) gene therapy for adults  
Via Benzinga
Amazon Hires Dozens of Former FTC Officials, Volkswagen Discusses With Tesla to Adopt North American Charging Standard, FDA Approves First Hemophilia A BioMarin Gene Therapy: Today's Top Stories
New York Post 
Via Benzinga
BioMarin's Delayed Roctavian Scores FDA Nod As First Hemophilia A Gene Therapy In US
The FDA approved BioMarin Pharmaceutical Inc's (NASDAQ: BMRN) Roctavian (valoctocogene roxaparvovec-rvox) gene therapy for adults with severe hemophilia A (congenital factor VIII (FVIII) deficiency... 
Via Benzinga
NVIDIA To Rally Over 16%? Here Are 10 Other Analyst Forecasts For Friday
Truist Securities boosted the price target for BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from $125 to $140. Truist Securities analyst Robyn Karnauskas maintained a Buy rating. BioMarin Pharmaceutical... 
Via Benzinga
3 Biotech Stocks to Buy With Explosive Upside Potential
These three biotech stocks with high upside potential also display some significant risk, but less so than many of their small-cap peers. 
Via InvestorPlace
NASDAQ: BMRN Long Term Investor Notice: Lawsuit Against Directors at BioMarin Pharmaceutical Inc. Filed
San Diego, CA -- (SBWIRE) -- 06/20/2023 -- The Shareholders Foundation announced that an investor in shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) filed a lawsuit against certain directors of... 
Via SBWire
3 Biotech Stocks That Could Skyrocket in the Next 12 Months
These promising biotech stocks are risky but offer tremendous upside generating stellar long-term returns in the upcoming 12 months. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
3 Biotech Stocks With Blockbuster Potential
Although risky, these biotech stocks with blockbuster potential may skyrocket should regulatory winds favor their therapeutics. 
Via InvestorPlace
Why PTC Therapeutics Could Be Victorious In Its Rare-Disease Battle Against BioMarin Pharmaceuticals
The company is working on a treatment for PKU, a disorder that can lead to intellectual disabilities. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.